Evidence map›Paper›PMID 38794284›Full record

ArticlePharmaceutics2024

A Novel 2-Methoxyestradiol Derivative: Disrupting Mitosis Inhibiting Cell Motility and Inducing Apoptosis in HeLa Cells In Vitro.

Isaac Kinyua Njangiru, Noémi Bózsity-Faragó, Vivien Erzsébet Resch, Gábor Paragi, Éva Frank, György T Balogh, István Zupkó, Renáta Minorics

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Isaac Kinyua NjangiruInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0009-0008-6733-0609
Noémi Bózsity-FaragóInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0002-7907-7734
Vivien Erzsébet ReschDepartment of Medicinal Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary.
Gábor ParagiDepartment of Medicinal Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary.ORCID 0000-0001-5408-1748
Éva FrankDepartment of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, H-6720 Szeged, Hungary.ORCID 0000-0002-1332-0551
György T BaloghInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0001-8273-1760
István ZupkóInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.ORCID 0000-0003-3243-5300
Renáta MinoricsInstitute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.

Funding

Hungarian Research Foundation (NKFI) K143690Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund TKP2021-EGA-17Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund TKP2021-EGA-32
6 · The paper itself

Abstract

The clinical application of 2-methoxyestradiol (2ME) in cancer therapy has been limited by its low solubility and rapid metabolism. Derivatives of 2ME have been synthesised to enhance bioavailability and decrease hepatic metabolism. Compound

Indexed as

anticancerapoptosiscell cyclemetastasismolecular dockingtubulin

Identifiers

PMID38794284
PMCPMC11125453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.